2-Phenyl-4-piperazinylbenzimidazoles: Orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor

Add time:07/18/2019    Source:sciencedirect.com

Antagonism of the gonadotropin releasing hormone (GnRH) receptor has shown positive clinical results in numerous reproductive tissue disorders such as endometriosis, prostate cancer and others. Traditional therapy has been limited to peptide agonists and antagonists. Recently, small molecule GnRH antagonists have emerged as potentially new treatments. This article describes the discovery of 2-phenyl-4-piperazinylbenzimidazoles as small molecule GnRH antagonists with nanomolar potency in in vitro binding and functional assays, excellent bioavailability (rat %F > 70) and demonstrated oral activity in a rat model having shown significant serum leuteinizing hormone (LH) suppression.

We also recommend Trading Suppliers and Manufacturers of 4-(2,4-Diaminophenyl)benzoic acid (cas 105868-35-7). Pls Click Website Link as below: cas 105868-35-7 suppliers

Prev:Dihydroxy acidissiminol and acidissiminol epoxide, two tyramine derivatives from Limonia acidissima
Next:Effect of (r)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) and AZT–lipid–PFA on human herpesvirus-6B infected cells)